Stockreport

Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma

NEWLINK GENETICS  (NLNK) 
Last newlink genetics earnings: 2/28 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.linkp.com/investor-relations
PDF Pivotal Trial of Indoximod in Advanced Melanoma to Include Both PD-1 Inhibitors, KEYTRUDA (pembrolizumab) and OPDIVO® (nivolumab) AMES, Iowa-- [Read more]